Company Overview
Nyrada is a drug discovery and development company, specialising in novel small molecule drugs to treat neurological and cardiovascular diseases. We are listed on the Australian Securities Exchange (ASX) under the ticker ASX:NYR.
Nyrada’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early-stage drug development. Our drug development programs focus on areas of substantial unmet clinical need where few if any, effective or well-tolerated therapies exist.
Nyrada has two lead drug development programs:
Neuroprotection Program: a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke
Cardioprotection Program: an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
Nyrada’s Neuroprotection Program is developing a drug to block secondary brain damage that occurs following a stroke or traumatic brain injury (TBI), such as severe head trauma from contact sports, a fall, or a motor vehicle accident.
Each year, globally, more than 60 million people suffer a concussion or moderate to severe traumatic brain injury[2], yet no FDA-approved treatment for secondary brain injury exists. For stroke the need is similar, with only limited treatment options available. In the US, a stroke occurs every 40 seconds and a TBI every 15 seconds. The combined economic burden for stroke and TBI, in the US amounts to more than US$100 billion in direct and indirect costs.
Nyrada’s objective is to reduce the long-term disability associated with stroke or traumatic brain injury by limiting the number of brain cells that die post injury.
Treatment with a neuroprotectant drug is intended to improve patient outcomes and increase the likelihood of recovery, shorten rehabilitation times, and reduce the economic burden to the health system.
Nyrada’s Cardioprotection Program is developing an oral, small molecule drug that effectively lowers cholesterol. The mechanism of action is via the inhibition of the plasma protein, PCSK9, an action known to assist standard-of-care statin drugs in achieving target cholesterol levels. Our objective is to combine our PCSK9 inhibitor with a generic statin into a single tablet, offering a novel, convenient dual-purpose medication, replacing expensive and inconvenient injectable PCSK9 inhibitor drugs.
More than 62 million Americans have risk factors associated with cardiovascular disease and are therefore eligible for cholesterol-lowering treatment.[1] From this population, approximately 27 million take a statin drug, however, more than 18 million, or close to 70% are unable to achieve their safe target cholesterol level. With a global aging population, patient need for new, more effective, and convenient cholesterol-lowering medication will only increase.
[1] Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016.
[2] National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A Roadmap for Accelerating Progress. Washington, DC: The National Academies Press. https://doi.org/10.17226/25394
